Pono Capital Two, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTWOU research report →
Price Chart
About the company
Pono Capital Two, Inc. is a company primarily focused on executing a significant business combination, such as a merger, capital stock exchange, asset acquisition, stock purchase, or corporate reorganization, with one or more suitable enterprises. Its strategic intent is to identify and partner with businesses operating in a diverse array of high-growth sectors.
- CEO
- Darryl S. Nakamoto
- IPO
- 2022
- HQ
- Honolulu, HI, US
Get TickerSpark's AI analysis on PTWOU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $57.38M
- P/E
- 11.20
- PEG
- 0.59
- P/S
- 3.02
- P/B
- 1.89
- EV/EBITDA
- 5.00
- Div Yield
- 0.00%
- Gross Margin
- 72.02%
- Op Margin
- 39.89%
- Net Margin
- 27.26%
- ROE
- 19.38%
- ROIC
- 13.52%
Latest fiscal year · YoY change
- Revenue
- $173.61M-15.5%
- Gross Profit
- $127.28M-18.4%
- Op Income
- $67.49M
- Net Income
- $50.99M+9.4%
- EPS
- $0.50+4.2%
- OCF Growth
- +19.8%
- FCF Growth
- +29.8%
- 52W High
- $35.90
- 52W Low
- $12.00
- 50D MA
- $12.72
- 200D MA
- $12.62
- Beta
- 0.11
- RSI (14)
- 50
- Avg Volume
- 1.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SBC Medical said third-quarter growth re-accelerated, with revenue up 35% and adjusted EBITDA margin expanding to 47% as the company highlighted operating leverage, clinic expansion, and new growth initiatives in AI and longevity.· November 13, 2026
- Revenue rose 35% year over year to $59 million; operating income increased 66% and adjusted EBITDA was $28 million, with margin up 9 points to 47%.
- Same-clinic revenue for the first nine months reached $836 million, up 7% year over year, supported by 7.06 million customer visits (+9%) and average spend per visit of $290 (+4%).
- The clinic network expanded to 293 locations, up 36 year over year, and management said the business is benefiting from strategic pricing, higher clinic productivity, and new equipment/treatments.
- Management laid out a staged longevity plan through 2028, including blood biomarker testing starting in November 2026, a longevity center in 2027, and meaningful revenue contribution around 2028.
- Capital priorities remain M&A and de novo openings; management said it is not considering additional share buybacks right now despite improved liquidity and a net cash balance sheet.
Third quarter revenue was $59 million, up 35% year over year. Income from operations was $26 million, up 66% year over year, adjusted EBITDA was $28 million, and adjusted EBITDA margin was 47%, up 9 points year over year. Basic EPS was $0.15, up 25%. Management also said same-clinic revenue for the first nine months was $836 million, up 7% year over year; customer visits were 7.06 million, up 9%; unique customers were 2.26 million, up 10%; and average spend per visit increased 4% to $290. Forward-looking commentary was qualitative rather than formal guidance: management expects profitability to improve further, sees continued mid- to long-term growth, expects meaningful longevity revenue contribution around 2028, and said it believes clinic network growth can continue next year at roughly this year's pace while margins have room to expand.
Yuya Yoshida framed the quarter as evidence that SBC’s operating model is working, emphasizing that profit grew faster than revenue and that margin improvement should continue. He positioned the company’s next growth leg around longevity, AI, and U.S. expansion, arguing that SBC’s 293-clinic network gives it an advantage because it can move from diagnosis to intervention at scale. His tone was confident and assertive, but he also stressed concrete execution steps rather than abstract strategy.
No separate CFO spoke on the call; Yuya Yoshida handled the financial commentary. He pointed to the 35% revenue increase, 66% operating income growth, and 47% adjusted EBITDA margin as evidence of operating leverage from structural reform and higher clinic productivity. On capital allocation, he said SBC will prioritize cash for M&A and de novo clinic openings, noted that average daily trading value in October was about $1 million versus July, and said the company is not considering additional share buybacks at this time because liquidity is improving.
Analysts asked whether revenue and margin growth are sustainable and what AI could add; management said growth is supported by multiple engines, could fluctuate short term, but should continue over the medium to long term, and AI should lift profitability further. Questions on the U.S. strategy drew a response that OrangeTwist remains the main expansion vehicle, with one more clinic opening this quarter and a target of an additional 8-10 clinics in the next three to four months, while SBC-branded U.S. clinics could appear in the next 6 to 12 months. Analysts also pressed on governance and capital allocation; management said independent director selection is progressing and reiterated that buybacks are not a current priority despite the stock’s valuation discount.
The call presented a clear case for operating leverage: revenue, operating income, and EBITDA all grew strongly, while same-clinic metrics and network expansion both improved. Management also laid out multiple future growth vectors—AI efficiency gains, U.S. expansion, and longevity services—with a stated expectation of meaningful longevity revenue around 2028.
The longevity initiative is still early and management said revenue contribution is not expected until around 2028, so near-term impact is limited. The company also acknowledged intense competition in Japan, with some clinics exiting, and it still faces governance scrutiny, including the need to add independent directors. Additionally, management is prioritizing cash for M&A and clinic openings rather than buybacks, which may disappoint investors focused on capital returns.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 4.78M
- Float Shares
- 0
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Aikawa Yoshiyuki | sell | 465,000 |
| Apr 21, 26 | Aikawa Yoshiyuki | sell | 3,100,000 |
| Mar 6, 26 | Aikawa Yoshiyuki | sell | 4,422,900 |
| Mar 6, 26 | Aikawa Yoshiyuki | other | 44,229 |
| Mar 6, 26 | Aikawa Yoshiyuki | other | 44,229 |
| Apr 10, 25 | Yamazaki Miki | other | 0 |
| Sep 17, 24 | Aikawa Yoshiyuki | other | 0 |
| Sep 30, 24 | SAYAMA MIKE K | other | 15,000 |
| Sep 17, 24 | ZUU Co. Ltd. | other | 1,503,473 |
| Sep 19, 24 | ZUU Co. Ltd. | sell | 6,196 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTWOU coverage
Recent articles, reports, and earnings notes.
No research on PTWOU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTWOU report →